Published in PLoS One on March 13, 2014
A Comparison of Two Ways to Manage Anti-HIV Treatment (The SMART Study) | NCT00027352
Factors Associated With Plasma IL-6 Levels During HIV Infection. J Infect Dis (2015) 0.95
Sex, age, race and intervention type in clinical studies of HIV cure: a systematic review. AIDS Res Hum Retroviruses (2015) 0.86
Differential levels of soluble inflammatory markers by human immunodeficiency virus controller status and demographics. Open Forum Infect Dis (2015) 0.86
Interleukin 6 Is a Stronger Predictor of Clinical Events Than High-Sensitivity C-Reactive Protein or D-Dimer During HIV Infection. J Infect Dis (2016) 0.82
Elevated Soluble CD14 and Lower D-Dimer Are Associated With Cigarette Smoking and Heavy Episodic Alcohol Use in Persons Living With HIV. J Acquir Immune Defic Syndr (2015) 0.80
D-Dimer Levels before HIV Seroconversion Remain Elevated Even after Viral Suppression and Are Associated with an Increased Risk of Non-AIDS Events. PLoS One (2016) 0.78
Barriers to a cure for HIV in women. J Int AIDS Soc (2016) 0.75
Inflammation Related Morbidity and Mortality Among HIV-Positive Adults: How Extensive Is It? J Acquir Immune Defic Syndr (2017) 0.75
HIV and Obesity Comorbidity Increase Interleukin 6 but Not Soluble CD14 or D-Dimer. J Acquir Immune Defic Syndr (2017) 0.75
Prediction of creatinine clearance from serum creatinine. Nephron (1976) 64.02
CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med (2006) 22.76
Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med (2008) 13.72
Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med (2005) 5.94
Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis (2010) 5.35
Interleukin-2 therapy in patients with HIV infection. N Engl J Med (2009) 4.38
Sex differences in the Toll-like receptor-mediated response of plasmacytoid dendritic cells to HIV-1. Nat Med (2009) 4.22
Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation (2003) 3.76
Increased tissue factor expression on circulating monocytes in chronic HIV infection: relationship to in vivo coagulation and immune activation. Blood (2009) 2.92
Endothelial and antithrombotic actions of HDL. Circ Res (2006) 2.68
Changes in inflammatory and coagulation biomarkers: a randomized comparison of immediate versus deferred antiretroviral therapy in patients with HIV infection. J Acquir Immune Defic Syndr (2011) 2.21
Opportunistic disease and mortality in patients coinfected with hepatitis B or C virus in the strategic management of antiretroviral therapy (SMART) study. Clin Infect Dis (2008) 2.06
Factors associated with positive D-dimer results in patients evaluated for pulmonary embolism. Acad Emerg Med (2010) 1.95
HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trial. AIDS (2009) 1.88
D-dimer concentration increases with age reducing the clinical value of the D-dimer assay in the elderly. Intern Med J (2007) 1.84
HIV status, burden of comorbid disease, and biomarkers of inflammation, altered coagulation, and monocyte activation. Clin Infect Dis (2012) 1.83
D-dimer correlates with proinflammatory cytokine levels and outcomes in critically ill patients. Chest (2002) 1.61
Interleukin-6 stimulates coagulation, not fibrinolysis, in humans. Thromb Haemost (1996) 1.47
High-density lipoprotein particles and markers of inflammation and thrombotic activity in patients with untreated HIV infection. J Infect Dis (2010) 1.46
Pre-ART levels of inflammation and coagulation markers are strong predictors of death in a South African cohort with advanced HIV disease. PLoS One (2012) 1.31
Fibrin degradation product D-dimer induces the synthesis and release of biologically active IL-1 beta, IL-6 and plasminogen activator inhibitors from monocytes in vitro. Br J Haematol (1994) 1.27
Associations of factor VIIIc, D-dimer, and plasmin-antiplasmin with incident cardiovascular disease and all-cause mortality. Am J Hematol (2009) 1.26
Female hormones and thrombosis. Arterioscler Thromb Vasc Biol (2002) 1.20
Age, functional status, and racial differences in plasma D-dimer levels in community-dwelling elderly persons. J Gerontol A Biol Sci Med Sci (2000) 1.13
Common genetic variants associated with plasma fibrin D-dimer concentration in older European- and African-American adults. J Thromb Haemost (2008) 1.06
HIV replication alters the composition of extrinsic pathway coagulation factors and increases thrombin generation. J Am Heart Assoc (2013) 1.04
Association of D-dimer levels with all-cause mortality in a healthy adult population: findings from the MOLI-SANI study. Haematologica (2013) 1.02
Interleukin-6 and d-dimer levels are associated with vascular dysfunction in patients with untreated HIV infection. HIV Med (2010) 1.00
Fibrin degeneration product concentrations (D-dimers) in the course of ageing. Gerontology (1995) 0.97
Determinants of fibrin D-dimer in the Edinburgh Artery Study. Arterioscler Thromb Vasc Biol (1995) 0.92
Severity of peripheral atherosclerosis is associated with fibrinogen and degradation of cross-linked fibrin. Arterioscler Thromb (1993) 0.91
Inflammatory Markers Associated with Coronary Heart Disease in Persons with HIV Infection. Curr Infect Dis Rep (2011) 0.90
High circulating D-dimers are associated with ascites and hepatocellular carcinoma in liver cirrhosis. World J Gastroenterol (2008) 0.83
Hyaluronic acid levels predict increased risk of non-AIDS death in hepatitis-coinfected persons interrupting antiretroviral therapy in the SMART Study. Antivir Ther (2011) 0.83
Plasma D dimer: a useful marker of fibrin breakdown in renal failure. Thromb Haemost (1989) 0.81
African-American ethnicity is associated with higher plasma levels of D-dimer in adults with hypertension. J Thromb Haemost (2008) 0.79
Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med (2008) 13.72
Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet (2006) 10.72
Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis (2011) 7.41
Interleukin-2 therapy in patients with HIV infection. N Engl J Med (2009) 4.38
Inflammation, coagulation and cardiovascular disease in HIV-infected individuals. PLoS One (2012) 3.68
Changes in inflammatory and coagulation biomarkers: a randomized comparison of immediate versus deferred antiretroviral therapy in patients with HIV infection. J Acquir Immune Defic Syndr (2011) 2.21
Smoking-related health risks among persons with HIV in the Strategies for Management of Antiretroviral Therapy clinical trial. Am J Public Health (2010) 2.21
Cardiovascular risk factors associated with lower baseline cognitive performance in HIV-positive persons. Neurology (2010) 2.17
A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J Thromb Haemost (2011) 1.75
The evaluation of subcutaneous proleukin (interleukin-2) in a randomized international trial: rationale, design, and methods of ESPRIT. Control Clin Trials (2002) 1.73
Lipoprotein particle subclasses, cardiovascular disease and HIV infection. Atherosclerosis (2009) 1.66
Adjudicated morbidity and mortality outcomes by age among individuals with HIV infection on suppressive antiretroviral therapy. PLoS One (2014) 1.35
Severity of cardiovascular disease outcomes among patients with HIV is related to markers of inflammation and coagulation. J Am Heart Assoc (2014) 1.26
Interruption of antiretroviral therapy is associated with increased plasma cystatin C. AIDS (2009) 1.26
Factors associated with adherence amongst 5295 people receiving antiretroviral therapy as part of an international trial. J Infect Dis (2012) 1.25
Hepatitis B and C co-infection are independent predictors of progressive kidney disease in HIV-positive, antiretroviral-treated adults. PLoS One (2012) 1.16
Medium intensity oral anticoagulants versus aspirin after cerebral ischaemia of arterial origin (ESPRIT): a randomised controlled trial. Lancet Neurol (2007) 1.08
Dipyridamole in stroke prevention: effect of dipyridamole on blood pressure. Stroke (2003) 1.02
Inflammation predicts changes in high-density lipoprotein particles and apolipoprotein A1 following initiation of antiretroviral therapy. AIDS (2011) 1.01
Boosted protease inhibitors and the electrocardiographic measures of QT and PR durations. AIDS (2011) 0.91
Glomerular filtration rate estimated using creatinine, cystatin C or both markers and the risk of clinical events in HIV-infected individuals. HIV Med (2013) 0.90
Changes in lipids and lipoprotein particle concentrations after interruption of antiretroviral therapy. J Acquir Immune Defic Syndr (2010) 0.89
Short communication: CD4 T cell declines occurring during suppressive antiretroviral therapy reflect continued production of Casp8p41. AIDS Res Hum Retroviruses (2014) 0.87
Biomarkers and bacterial pneumonia risk in patients with treated HIV infection: a case-control study. PLoS One (2013) 0.86
HIV replication, inflammation, and the effect of starting antiretroviral therapy on plasma asymmetric dimethylarginine, a novel marker of endothelial dysfunction. J Acquir Immune Defic Syndr (2012) 0.86
Biomarkers of inflammation, coagulation and microbial translocation in HIV/HCV co-infected patients in the SMART study. J Clin Virol (2014) 0.85
Platelet count kinetics following interruption of antiretroviral treatment. AIDS (2013) 0.83
Haemoglobin and anaemia in the SMART study. Antivir Ther (2011) 0.82
Use of surveillance data on HIV diagnoses with HIV-related symptoms to estimate the number of people living with undiagnosed HIV in need of antiretroviral therapy. PLoS One (2015) 0.81
Electrocardiographic spatial QRS-T angle and incident cardiovascular disease in HIV-infected patients (from the Strategies for the Management of Antiretroviral Therapy [SMART] study). Am J Cardiol (2012) 0.81
Relative risk of death in the SMART study. Lancet Infect Dis (2009) 0.79
The feasibility of clinical endpoint trials in HIV infection in the highly active antiretroviral treatment (HAART) era. Clin Trials (2006) 0.79
Improved neurocognitive test performance in both arms of the SMART study: impact of practice effect. J Neurovirol (2013) 0.78
Severity of cerebral white matter lesions and infarcts in patients with transient or moderately disabling cerebral ischaemia: reproducibility of grading by neurologists. Eur J Neurol (2006) 0.78
Protease inhibitors and cardiac autonomic function in HIV-infected patients: a cross-sectional analysis from the Strategies for Management of Antiretroviral Therapy (SMART) Trial. BMJ Open (2013) 0.77
Biomarkers and electrocardiographic evidence of myocardial ischemia in patients with human immunodeficiency virus infection. Am J Cardiol (2012) 0.77
Oral anticoagulation in secondary prevention after cerebral ischemia of arterial origin. Stroke (2005) 0.75
Determinants of developing widened spatial QRS-T angle in HIV-infected individuals: results from the Strategies for Management of Antiretroviral Therapy [SMART] Study. J Electrocardiol (2013) 0.75
Interpretation of ESPRIT in the FASTER trial. Lancet Neurol (2008) 0.75